Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

MC, Heinrich; D, Griffith; A, McKinley; J, Patterson; A, Presnell; A, Ramachandran; M, Debiec-Rychter

doi:10.1158/1078-0432.ccr-12-0625

Public

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

Shared by NobleBlocks on Jun 27, 2012 • 12:00 AM UTC

Authors:

Heinrich MC

Griffith D

McKinley A

Abstract

Purpose To determine the potential of crenolanib, a potent inhibitor of PDGFRA, to treat malignancies driven by mutant PDGFRA.Experimental design The biochemical activity of crenolanib was compared with imatinib using a panel of PDGFRA-mutant kinases expressed in several different cell line models, ...

Discussions